Next Article in Journal
The Detection of Chlamydia pneumoniae, Helicobacter pylori and Cytomegalovirus in Non-Atherosclerotic Arteries of Patients with Coronary Artery Disease
Next Article in Special Issue
Two Decades of Melioidosis in India: A Comprehensive Epidemiological Review
Previous Article in Journal
McHDV VP60 Virus-like Particles Elicit Protective Immunity Against Moschus chrysogaster Hemorrhagic Disease in Rabbits
Previous Article in Special Issue
The Genomic Epidemiology of Clinical Burkholderia pseudomallei Isolates in North Queensland, Australia
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pathogens
Volume 13
Issue 11
10.3390/pathogens13110926
pathogens-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

The Evolving Global Epidemiology of Human Melioidosis: A Narrative Review

by
Francesca F. Norman
1,2,3,*,
Barbra M. Blair
4,5,
Sandra Chamorro-Tojeiro
1,2,
Marta González-Sanz
1,3 and
Lin H. Chen
5,6
1
National Referral Unit for Tropical Diseases, Infectious Diseases Department, Ramón y Cajal University Hospital, IRYCIS, 28034 Madrid, Spain
2
CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, 28029 Madrid, Spain
3
Health Sciences, Universidad de Alcalá, 28801 Madrid, Spain
4
Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA 02114, USA
5
Harvard Medical School, Boston, MA 02115, USA
6
Department of Medicine, Mount Auburn Hospital, Cambridge, MA 02138, USA
*
Author to whom correspondence should be addressed.
Pathogens 2024, 13(11), 926; https://doi.org/10.3390/pathogens13110926
Submission received: 15 September 2024 / Revised: 16 October 2024 / Accepted: 18 October 2024 / Published: 24 October 2024
(This article belongs to the Special Issue Updates on Human Melioidosis)
Browse Figure
Versions Notes

Abstract

:
Endemic in over 45 countries globally, recent reports of locally acquired melioidosis in novel geographical areas, such as the Southern US, have highlighted the expanding geographical range of Burkholderia pseudomallei. Climate change and severe weather events have been linked to an increase in cases of melioidosis, which follows environmental exposure to the bacterium. Healthcare professionals should be aware of the possibility of the disease, with its diverse and often delayed presentations, even in areas not previously known to have risk. Over 200 cases of travel-associated melioidosis have been reported in the literature, highlighting the need to consider this disease in non-endemic areas, as diagnostic delays of up to 18 months have been identified. The review updates the global epidemiology of melioidosis, focusing on new geographical areas where cases have been diagnosed and imported cases, unusual clinical presentations and co-infections, and less frequent modes of transmission (laboratory exposures and the risk of acquisition due to imported infected animals and contaminated products).

1. Introduction

The recent report of locally acquired melioidosis in the Southern USA highlighted the expanding geographical range of Burkholderia pseudomallei [1]. Officially present in around 45 countries worldwide, mainly in Asia, modeling studies suggest underreporting and much wider geographical distribution, with autochthonous cases described in Africa, America and the Caribbean [2,3].
Climate change and severe weather events have been linked to an increase in cases of melioidosis, which follows environmental exposure to the bacterium [4,5]. An outbreak of melioidosis occurring during two La Niña events in an Australian region previously considered non-endemic for B. pseudomallei was notified recently [5]. However, traditional risk factors may not always be present, as documented by another outbreak of localized cutaneous melioidosis in immunocompetent children in Australia following a sporting event during the dry season [6]. In the context of the recent COVID-19 pandemic, new scenarios have also arisen, as illustrated by an outbreak of acute melioidosis in patients with SARS-CoV-2 infection linked to contact with contaminated tap water in a field hospital in Thailand [7].
The role of population movements in the epidemiology of infectious diseases must also be considered. Two reviews on travel-related melioidosis spanning 1982–2022 analyzed over 200 cases and presented a picture of the main characteristics of imported infections, mainly acquired by males (>70%), in Asia (>70%), with pneumonia and sepsis as the most frequent presentations and diabetes mellitus and chronic lung disease as frequent co-morbidities [8,9]. These reviews noted both acute and latent presentations and emphasized the increasing identification of melioidosis in areas not previously associated with high risk; around 15% of travel-related infections were acquired in the American continent/Caribbean area and in Africa. Additional infections in travelers have been reported in 2023 and 2024 [10,11]. Risk groups such as immunocompromised patients merit special consideration, and expert recommendations relating to regionally limited bacterial infections like melioidosis in hematopoietic stem-cell transplantation donors and recipients have recently been updated [12].
Healthcare professionals should be aware of the possibility of the disease, with its diverse and often delayed presentations, even in areas not previously known to have risk. Lack of clinical suspicion may have further consequences with the inadvertent exposure of individuals such as laboratory personnel, leading to evaluation for post-exposure prophylaxis and extensive contact tracing and monitoring [13].
The review updates the changing global epidemiology of melioidosis to enhance awareness among healthcare professionals, focusing on new geographical areas where cases have been diagnosed and imported cases, unusual clinical presentations, data on special populations such as immunosuppressed patients, co-infections and less frequent modes of transmission (laboratory exposures and risk of acquisition due to imported infected animals and contaminated products).

2. Updates in Global Epidemiology

Melioidosis has classically been described in Southeast Asia and Northern Australia [14]. The disease has been spreading to new geographical areas in Asia, and it has also affected other continents, such as Africa and America [15,16,17,18]. B. pseudomallei originated in Australia, with subsequent introduction into Asia, and anthropogenic factors may have assisted in B. pseudomallei dissemination to Africa. Phylogenomic analysis of isolates has shown that African strains probably originated from Asia and were related to South American strains, possibly reflecting a recent shared evolutionary history [19].
Recently, cases of melioidosis have been reported in the US Gulf Coast of Mississippi in patients with no travel history, where the acquisition probably followed environmental exposure as the bacterium was found in soil samples [1]. This has triggered the Centers for Disease Control to consider melioidosis an endemic infection in the US [20,21]. Other Public Health interventions highlighted the need to strengthen disease awareness and diagnostics, emphasizing the risk of misdiagnosis with some microbiological platforms [21,22]. Public Health preparedness also includes surveillance, building laboratory capacity (biosafety level 3 is required) and developing training and protocols; adequate financial support must be allocated to perform these activities [22].
Melioidosis should also be considered in patients with suggestive clinical features who have traveled to any of the novel geographical areas [22]. Regarding imported melioidosis, previous reviews up to 2015 [9] and from 2016 to 2022 [8] showed that the most frequent regions of acquisition and diagnosis were Asia (mainly Thailand) and Western Europe, respectively. Table 1 summarizes the previous literature reviews on travel-associated melioidosis and outlines the main characteristics for ten additional cases reported from 2023 to mid-2024 [8,9,10,11,23,24,25,26,27,28,29,30]. These cases were identified following a search in PubMed (https://pubmed.ncbi.nlm.nih.gov, accessed on 30 June 2024) and Google Scholar (http://scholar.google.com, accessed on 30 June 2024) for articles in English using the terms melioidosis and Burkholderia pseudomallei (January 2023–June 2024). These ten most recent cases were also mainly acquired in Asia (8/10, 80%), with one case linked to exposure in Africa (Mauritania) and another in Central America (Honduras). Diabetes was the main identified risk factor (7/10, 70% and one other patient with pre-diabetes), although one case had no known risk factors. Due to the geographical expansion of the distribution of the disease and the increasing trend in international travel, imported melioidosis is being reported worldwide with novel geographical areas featuring as countries of acquisition [31].

3. Clinical Manifestations Including Less Usual Presentations

Melioidosis can manifest with wide-ranging clinical presentations in patients living in endemic areas as well as travelers, most frequently with pneumonia [8,32,33,34]. Over half the cases have bacteremia, and 20% develop septic shock. Infection can involve any body site and organ, including abscesses on the skin and soft tissues, in the liver or spleen, genitourinary tract infections, bone and joint infections, encephalomyelitis, meningitis or brain abscesses, gland abscesses such as parotid, and bacteremia without focal site. Skin infections were commonly reported, especially among children in Australia, usually occurring as a single abscess without sepsis [32,33]. In some Southeast Asian countries, parotid abscesses are the most common presentation in children [32]. Genitourinary sepsis with prostatic abscesses is especially common in males in Australia, and female genitourinary tract infections also occur [32,33,35].
A 30-year analysis of 1148 patients diagnosed with melioidosis in an endemic area at the Royal Darwin Hospital identified the majority of cases to be acute (88%), while 9% were chronic and 3% were reactivation; among deaths, 12% were attributable to melioidosis. Pneumonia was the main diagnosis in 52% of cases, skin abscesses in 13%, and genitourinary infection in 12% of cases. The latter involved mainly males (74%) who had prostatic abscesses. Eleven percent of cases presented with bacteremia without a focal site of infection, and these tended to be immunocompromised patients. Children were far more likely to present with skin abscesses compared to adults (58% vs. 11%) and less likely to have bacteremia compared to adults (15% vs. 58%) [33].
Separately, a prospective multi-center cohort study of 1352 patients from northeastern Thailand, a highly endemic region, also found lung infection to be the most common presentation (42%), which is associated with increased risk for death. Sixty percent of all deaths in one month can be attributed to lung infection. Skin and soft tissue infections were less common (23%) and had lower mortality at one month (14%). In this cohort, B. pseudomallei bacteremia was present in 77% [34].
Among travel-related cases, the frequently reported presentations included pneumonia (35%), sepsis (29%), skin/soft tissue infections (14%), genitourinary involvement (including prostatic abscess) (11%), CNS involvement (9%) and endovascular infections (mycotic aneurysms, prosthetic valve infections, pericardial effusion) (6%) [8].

3.1. Pediatric Melioidosis

Most studies and reviews that described pediatric melioidosis cases generally found only a small proportion to occur in children and with a higher proportion of skin and soft tissue infections in children compared to adults [6,32,33]. Although invasive disease can also occur in children, Burkholderia pseudomallei infection in children can be subclinical; some evidence from a seroprevalence study in Thai children aged <15 years estimated symptomatic disease to occur only in 1 out of 4600 antibody-producing exposures [36]. The most frequent cutaneous manifestations are solitary abscesses [32,33], but multiple pustules and cellulitis also occur, and erythema nodosum has been reported in children with melioidosis, all involving lower limbs [37,38,39].
Head and neck involvement of melioidosis has been reported frequently in children [40,41,42]. Among 34 children with culture-confirmed melioidosis in Sarawak, Malaysia, 59% had an infection located on the head or neck [42]. Infected sites include cervical lymph nodes (95%), salivary gland (25%), and, less commonly, lacrimal gland (dacryocystitis) and scalp abscesses. An analysis describing a 10-year experience (2009–2018) with 355 children with culture-confirmed melioidosis in northern Cambodia reported that parotitis was the most frequent presentation, found in 27% of the cohort. In this pediatric population, the in-hospital case fatality rate was 11.5%; risk factors for death included bacteremia, pneumonia, female sex, and age <5 years [40]. Notably, this study reported that some children (n = 39) recovered after treatment solely with oral antimicrobial drugs, which suggests a milder course in some pediatric melioidosis patients [40].
Another recent retrospective study from Vietnam analyzed 35 culture-confirmed melioidosis in children <16 years of age between July 2015 and August 2019. This series also found suppurative parotitis to be the most common presentation (43%), followed by lung infection (29%) with disseminated disease, septicemia (20%), and less commonly central nervous system symptoms (11%); case fatality was still high at 11% [41].
In a systematic review that identified 22 cases of neonatal melioidosis (acquired through mother-to-child transmission, healthcare-associated or community-acquired infections), B. pseudomallei sepsis and/or pneumonia and/or meningitis were the most frequent diagnoses, with clinical presentations including fever and respiratory distress but also nonspecific symptoms such as poor feeding, lethargy, and grunting [43].

3.2. Genitourinary Manifestations

In adults, pneumonia is the most frequent presentation of melioidosis, but genitourinary infections are also commonly reported in patients living in endemic areas and also in international travelers, including prostatitis, prostate abscess, urinary tract infection [9,29,35,44,45]. Among 514 patients with 561 episodes of melioidosis from the Northern Territory, Australia, 70% of the patients were male [46]. Prostatic abscesses were identified in 21% of these episodes, usually by computerized tomography. Another series of 144 culture-confirmed melioidosis cases in men in Far North Queensland, Australia, from January 1998 through June 2017, found that all patients with prostatic abscess (n = 22, 15%) were adults aged> 18 years. The majority of patients with prostatic abscesses had symptoms such as dysuria, urgency, frequency, retention or incontinence, or positive urine culture for B. pseudomallei, but prostate tenderness was present in less than half [44,46]. Relapse of prostatic abscess is common; hence, surgical drainage is important for many of these patients [44].
Genitourinary infections in women have also been reported, though less frequently than in men [35]. Among 453 cases of melioidosis in Far North Queensland, Australia, evaluated between January 1998 and April 2023, 9% of women (13/140) had genitourinary involvement compared to 24% in men. The majority of these women (85%) also had other organ involvement, and two with only genitourinary tract disease had pre-existing anatomical defects. Genitourinary involvement was identified only with computed tomography in 23% of the affected women, underscoring the need for early imaging to identify unexpected sites of disease [35].
Complications such as chorioamnionitis and premature delivery due to B. pseudomallei infection during pregnancy have been reported. In one instance, placental infection occurred despite prolonged ceftazidime therapy [47].

3.3. Cutaneous Presentations

Skin and soft tissue involvement in melioidosis is estimated to occur in about 13–14% of melioidosis cases, with some series reporting higher proportions (e.g., the Australian pediatric patients and one report on European travelers) [33,37,48]. The clinical presentation of cutaneous melioidosis ranges from localized dermatologic findings such as a single skin lesion without systemic symptoms (primary cutaneous melioidosis) to multiple pustules as a result of the bacteremic spread of B. pseudomallei to the skin (secondary melioidosis) [49]. The manifestations are widely varied, including ulcers, abscesses, cellulitis, pustules, boils, and carbuncles, and less frequently, erythema nodosum, polyarteritis nodosa, Sweet syndrome, ecthyma-like lesions, necrotizing fasciitis, and extensive skin pustular eruption with sepsis [37].
A summary of 43 cases of cutaneous melioidosis (CM) from the literature published before January 2018 found that the majority (67.4%) were travelers, with nearly half returning from Thailand. Most of the resident cases occurred in China. The majority of this cohort (88%) had primary CM, including 30% with chronic infection. Half of the primary CM patients had only skin lesions, and the other half also had additional sites of involvement. The median incubation time was 3 weeks.
The skin manifestations were similar between travelers and residents, most commonly with skin abscesses (58%), followed by cellulitis (26%) and skin ulceration (21%). Infection most frequently involved legs and feet, and less commonly, head and neck (22%), arms and hands (19%), trunk (11%), and disseminated infection (5%). Among the secondary CM patients, abscesses were common (60%), one patient had inflammatory leg swelling (20%), and one had disseminated pustules (20%). All secondary CMs presented with an acute form. About a third (37%) underwent surgery. Death was reported in less than 5% [49].

3.4. Hemophagocytic Lymphohistiocytosis (HLH)

At least five cases of HLH, a severe inflammatory syndrome due to the excess activation of macrophages and T cells, complicating melioidosis, have been reported in the literature [50,51,52,53,54]. These cases were reported mainly from endemic areas (two cases from India, one from China and one from Australia), with one case diagnosed in New Zealand but probably acquired in Brunei. Two of these cases were fatal, and the other three patients survived (although one of the latter, occurring in a primigravida, medical termination of pregnancy was performed due to severe intrauterine growth restriction of the fetus).
Recognizing this potentially life-threatening condition, which may be triggered by various viral and bacterial infections, hematological malignancies and connective tissue diseases, among others, is essential, as the early initiation of specific therapies such as high-dose corticosteroids may be necessary in addition to the required antibiotics.

4. Melioidosis in Special Populations

The main predisposing risk factors for melioidosis are diabetes mellitus, hazardous alcohol intake, chronic renal and pulmonary disease, and immunosuppression, although a direct association between HIV infection and the risk of melioidosis has not clearly been established [55]. In the future, the occurrence of melioidosis in special risk groups may increase; the 30-year investigation of over 1100 patients with culture-confirmed melioidosis in northern tropical Australia found that over the three decades, there was a significant increase in the proportion of patients over 50 years of age, females, with diabetes, malignancy, and immunosuppression, whereas there was a significant decrease in patients with no risk factors [33]. This study found that 10% of patients had underlying malignancies and 9% received immunosuppressive therapy/had other forms of immunosuppression, and associated mortality in these groups was 18% and 17%, respectively, similar to that reported for some of the other risk groups, such as patients with rheumatic heart disease/congestive cardiac failure or chronic renal disease [33]. Another study from an endemic region in Thailand, analyzing the characteristics of 1352 patients with culture-confirmed melioidosis, found that although most patients had risk factors for the infection, patients without identified risk factors did not have a decreased risk of death, highlighting possible gaps in the knowledge of the pathophysiology of the disease [34].

4.1. Solid Organ Transplant Patients

There are several cases of melioidosis in solid organ transplant recipients (SOTR) reported in the literature. Most of these reports are from Australia and Southeast Asia, especially India [56,57,58,59,60]. In addition, of the cases reported, many are in renal transplant recipients who also had concomitant diabetes mellitus, a known risk factor for melioidosis [61]. The most common clinical presentation is an acute febrile illness with pneumonia, yet as the nickname given to melioidosis as “the great mimicker” suggests, there are many other clinical syndromes attributable to it, including visceral abscesses involving the liver, spleen, kidney and prostate; septic arthritis; and osteomyelitis [62]. Further, the immunosuppression associated with organ transplantation can reactivate latent infection with B. pseudomallei, posing a significant problem [62]. Thus, it is recommended that patients living in or from melioidosis-endemic regions or those with evidence of past exposure to B. pseudomallei should be screened for melioidosis prior to solid organ transplantation [62,63]. Additionally, recommendations for preventing exposure to B. pseudomallei are increasingly important, especially for solid organ transplant recipients residing in or visiting endemic areas by limiting exposure to soil and surface water by avoiding gardening and other risk activities during the wet season and wearing protective foot-wear and protective gear during such activities [62,63]. Trimethoprim–sulfamethoxazole (TMP-SMX), which may protect against melioidosis and prophylaxis, especially in the early post-transplant period or times of increased immunosuppression, could be considered in high-risk situations [62]. More importantly, melioidosis needs to be included in the differential diagnosis of fever of unknown origin in transplant recipients who have traveled to endemic areas, especially since diagnosis can be difficult if not considered [62]. Once diagnosed, treatment of melioidosis in the SOTR is accomplished in two phases. First, an intensive phase with a beta-lactam, usually ceftazidime or a carbapenem such as meropenem, is given for at least 14 days but up to 8 weeks if severely ill, followed by an eradication phase with TMP-SMX or doxycycline for at least 3 months [57,58,62,63]. B. pseudomallei is an important and likely underreported emerging pathogen among organ transplant recipients. In order to prevent mortality, all clinicians, but especially those from non-endemic regions, need to be aware of its existence and have a high index of suspicion for patients originally from or with recent travel to endemic areas.

4.2. HIV

Although immunosuppression has been recognized as a risk factor for human melioidosis, data on HIV and B. pseudomallei co-infection are limited [55].
In a retrospective study in northeast Thailand, co-infection was detected in a minority (8/524, 1.5%) of adults with melioidosis, and both clinical presentation and acute outcomes were found to be similar in HIV-positive and HIV-negative patients [64].
In the recent series reviewing travel-associated melioidosis, only 2% of patients (3/137) also had an HIV infection [8]. Of these, two had favorable outcomes, and the patient who died was a diabetic migrant presumed to have a latent melioidosis infection that was reactivated by COVID-19 [65,66,67].

4.3. Malignancy

Co-existence of melioidosis and malignant neoplasms appears to be infrequent; rather, there have been reports of atypical presentations of B. pseudomallei infections in which malignancy was initially suspected or that were initially misdiagnosed as tumors, mainly with pulmonary involvement [68,69,70].
Several reports have notified cases of melioidosis in patients with cancer. Four cases of melioidosis, with an associated 50% mortality rate, in the context of febrile neutropenia in patients receiving chemotherapy have been published [71,72,73]. A non-diabetic renal transplant recipient from Thailand with a rare simultaneous presentation of localized pulmonary Burkholderia pseudomallei infection and primary pulmonary adenocarcinoma has also been reported [74]. Reported associations of melioidosis with hematological malignancies are rare and include an unusual description of the infection and hairy cell leukemia in two travelers returning from Thailand [75]. The review of imported melioidosis identified three patients with underlying malignancies; two had hematologic malignancies (Non-Hodgkin’s lymphoma and multiple myeloma) and survived, and one fatal case was also diagnosed with malignant undifferentiated carcinoma [8,76,77,78,79].

4.4. Other Causes of Immunosuppression

Data on B. pseudomallei infection in patients with other causes of immune suppression are scarce. A patient with psoriatic arthritis, living in an endemic area, who had received therapy with etanercept, ustekinumab and adalimumab was diagnosed with B. pseudomallei bacteremia following mild skin trauma while gardening after a period of heavy rainfall [80]. An uncommon presentation of severe melioidosis in a female with newly diagnosed systemic lupus erythematosus has also been reported [81].
B. pseudomallei infections in special populations and the possible association of melioidosis with novel immunosuppressive therapies and/or conditions require further investigation.

5. Co-Infections

Co-infection with melioidosis is uncommon but has been occasionally reported, particularly during outbreaks. These co-infections can complicate the clinical presentation and outcomes, making both diagnosis and treatment more challenging. Co-infections may involve viruses, bacteria, mycobacteria, or parasites. This section reviews some of the co-infections with Burkholderia pseudomallei and other microorganisms that have been reported in the literature to date.

5.1. Melioidosis and Viral Diseases

In endemic areas, dengue fever may coexist with melioidosis, complicating the diagnosis since both can present with fever, myalgia, and other nonspecific symptoms. A fatal case has been reported in Brazil in a young man with prolonged respiratory symptoms [82,83]. The inclusion of melioidosis in the reported differential diagnosis of community-acquired infections is mandatory in countries where both melioidosis and dengue fever are endemic because of the poor prognosis.
A case of melioidosis and Japanese encephalitis was reported in China in a 52-year-old man with fever, headache and respiratory symptoms. Neurological melioidosis is rare, accounting for only 5% of all melioidosis, and is therefore not often misdiagnosed. In this case, both JEV and B. pseudomallei infections were identified with different diagnostic tools in cerebrospinal fluid and blood [84].
The ongoing SARS-CoV-2 pandemic has also raised concerns about COVID-19 and melioidosis co-infections, particularly because both diseases can cause severe pneumonia and sepsis and could be especially severe in immunosuppressed patients. A nosocomial outbreak involving COVID-19 patients who developed acute melioidosis is further discussed below [7]. Another fatal case of reactivation of latent melioidosis associated with COVID-19 in a patient with risk factors has also been reported, as mentioned previously [67]. The reactivation of latent infections, such as melioidosis among immunosuppressed patients who develop COVID-19, should be considered.
Seasonal influenza may exacerbate the respiratory symptoms of melioidosis, leading to a more severe clinical course. A case of concurrent pulmonary melioidosis and influenza A in a pregnant woman has been described in Malaysia [85]. Influenza A is usually a self-limiting disease but is associated with high morbidity and mortality in high-risk populations, particularly during pregnancy. As both microorganisms can cause pneumonia, their diagnosis and management are challenging, and their prognosis may be poor without adequate antibiotic therapy. Influenza has also been associated with the reactivation of latent melioidosis, as illustrated by a report on a Vietnam veteran with sepsis following the activation of melioidosis in the setting of influenza [86].

5.2. Bacterial and Mycobacterial Co-Infections

Co-infection of tuberculosis and melioidosis is rare, with only 15 cases reported up to 2023, mostly in India [87] and the western Pacific region [88]. A mathematical estimate for Thailand of concurrent melioidosis and TB estimated an extremely low incidence of 0.0085 per 100,000 people [89]. Most of the notified cases have involved infections at the same anatomical site, primarily the lungs, though less common sites include cervical abscesses and lumbar spondylodiscitis. Only one case has been documented with simultaneous infections in different locations (pulmonary and digestive tuberculosis and a splenic abscess caused by B. pseudomallei) [88,90,91]. Diabetes mellitus is the most frequently identified risk factor, and there is a noted predominance of males among those affected [88]. In many cases, the co-infection was discovered incidentally through examination of respiratory samples, tissue biopsies, or blood samples [88].
Leptospirosis with melioidosis has been reported, mainly in Southeast Asia and northern Australia. Both diseases share similar environmental reservoirs, being associated with exposure to contaminated soil and water, especially during the rainy season. The biggest outbreak involving co-infection with these two bacteria has been described in a recreational forest in Malaysia (Lubuk Yu), where 153 people were exposed, including professional rescuers and villagers; 10 had a confirmed diagnosis of melioidosis, and 4 of those were co-infected with leptospirosis with a 70% of case fatality rate. Diabetes was a common risk factor among fatal cases [92,93]. Few other cases have been documented [94,95].
Complementary laboratory tests, including molecular tests [96], are essential for accurate diagnosis and management in cases where both infections may be involved and should include adequate coverage [95].
Cat scratch disease, caused by Bartonella spp., has become more frequent in certain geographical areas, especially among infants. A case of cat-scratch disease and melioidosis co-infection in a two-year-old boy with prolonged fever and painless cervical lymphadenitis has been described in Malaysia [97]. A history of travel to endemic areas and exposure to cats may be key clues to the diagnosis.

5.3. Parasitic Co-Infections

A report of a Sri Lankan female patient with diabetes mellitus, B. pseudomallei bacteremia and cutaneous leishmaniasis has been notified [98]. Although leishmania and melioidosis are common in this area, very few cases of co-infection have been described. A search for cases of melioidosis in association with other relevant parasitic diseases, such as malaria, strongyloidiasis, schistosomiasis and Chagas disease, did not identify additional cases.
The low frequency, as well as the clinical manifestations and risk factors common to some of these diseases, make the diagnosis of co-infections a great challenge, especially in non-endemic areas. However, given the overlapping distribution areas of many of these tropical diseases, the burden of co-infections in the context of melioidosis may well be unrecognized.

6. Laboratory Exposure and Nosocomial Transmission

Laboratory-acquired melioidosis is extremely rare. That said, Burkholderia pseudomallei in culture presents a risk to laboratory workers because of a low infectious dose coupled with the ease with which it is aerosolized [99]. Thus, it is paramount that if melioidosis is suspected clinically, the microbiology laboratory personnel must be notified to ensure that full laboratory safety measures are implemented [13]. There have been reports of laboratory personnel infected via a variety of clinical samples when this organism was unfortunately not suspected or misidentified initially [100,101]. Thus, it is recommended that work with Burkholderia pseudomallei be conducted in a biological safety cabinet, and gloves should always be worn when manipulating this organism [100]. In the event of a potential laboratory exposure, management guidelines have been suggested that include immediately washing any site of potential exposure with copious amounts of water, with the exposed worker immediately undergoing risk assessment to determine whether the laboratory incident poses a low risk or a high-risk exposure by appropriate occupational medical staff [100]. All those involved in high-risk incidents and low-risk incidents in those with risk factors for melioidosis should be offered PEP for 21 days with oral TMP-SMX, amoxicillin–clavulanic acid or doxycycline; however, the data for efficacy in humans are lacking [100]. Additionally, the exposed laboratory worker should self-monitor temperature for 21 days and be instructed to seek medical attention for any febrile illness with or without a cough [100]. Serologic testing after exposure, especially in non-endemic areas, should be considered [13,100]. Finally, all microbiologic laboratories, but especially those in non-endemic areas, should be aware of the growth characteristics of B. pseudomallei to minimize the potential for occupational exposure.
Exceptionally, nosocomial transmission of B. pseudomallei has also been described. The first two reported cases of hospital-acquired infection due to Pseudomonas pseudomallei were notified in 1979 when the organism was isolated from urine samples from catheterized diabetic patients in an endemic area of Australia [102]. Following this report, another case, which had been initially diagnosed in the early 1970s, involving a pulmonary infection acquired from a contaminated bronchoscope in Hawaii, was published [103]. A systematic review of neonatal melioidosis identified 22 cases, four of which were probable healthcare-associated infections (two of them fatal) and occurred in Thailand (n = 3) and Malaysia (n = 1) [43].
A cluster of six healthcare-associated cutaneous melioidosis cases due to contaminated wound irrigation fluid was also reported in a non-endemic area of Australia [104]. More recently, 25 patients with COVID-19 were diagnosed with acute melioidosis, mainly secondary bacterial pneumonia (in 88% of these patients), after admission to a COVID-19 field hospital in Thailand. In-hospital mortality for these co-infected patients was high (8/25, 32%). Genomic analysis of environmental samples testing positive for B. pseudomallei suggested contaminated tap water as the likely cause of illness [7].
Occupationally acquired melioidosis has also been described. Two mechanics in northern Australia with upper limb cutaneous melioidosis were probably infected following exposure to contaminated commercial hand wash detergent [105].

7. Imported Contaminated Products

Four cases of melioidosis, each identified in Georgia, Kansas, Minnesota and Texas, were found to be caused by a strain of B. pseudomallei associated with an imported aromatherapy spray. These isolates were clonal and matched an isolate from a bottle of room spray, Better Homes and Gardens Brand, that originated from India, a melioidosis-endemic area [106].
The patients included a 53-year-old woman with a history of chronic obstructive pulmonary disease, a 53-year-old man with alcohol dependence and tobacco use, and a 4-year-old girl and a 5-year-old boy without underlying health conditions. Their clinical courses ranged from pneumonia and bacteremia to septic shock; meningoencephalitis; nausea and vomiting; cerebral infarcts; osteomyelitis; osteonecrosis; and abscesses in lungs, liver and brain. Two died, and two had long-term debilitating sequelae. The aromatherapy spray from a patient was confirmed to have Burkholderia pseudomallei of the same strain [106].
Following the cluster of four melioidosis cases, the investigation discovered the aromatherapy spray to be a potential cause of animal disease [1]. The incident involved a previously healthy pet raccoon, owned by the family of the 5-year-old boy, who had broken a bottle of the aromatherapy spray and walked through the material. Two weeks after the exposure, the animal manifested acute neurologic symptoms and died 3 days later. The investigation tested multiple samples taken from the animal and the environment after these events, and two swabs collected from the raccoon’s intraorbital tissue tested positive by PCR for B. pseudomallei, although cultures did not yield viable B. pseudomallei. All other tissue samples tested negative by PCR or IHC, and no environmental contamination was detected by both PCR and culture. The outbreak-related strain found in the aromatherapy bottle contained a genetic variant, the bimABm allele, which has been reported to be a virulence factor associated with neurologic melioidosis that is suspected to be the raccoon’s disease [1].
Another possible import-related exposure was described when a woman confirmed to have B. pseudomallei bacteremia was evaluated for possible environmental exposures. Three PCR-positive samples were obtained from her freshwater home aquarium with imported tropical fish, and whole-genome sequencing confirmed a genetic match with the patient’s clinical specimen. This incident raised the concern that the home aquarium materials or imported fish may be a source of melioidosis [107].

8. Imported Animals as Possible Sources

Melioidosis is not always considered a zoonosis; however, multiple animal species can be affected by Burkholderia pseudomallei. The trade of exotic animals has led to the emergence of cases in non-endemic regions [8,108]; this threat is ongoing, with cases recently being reported in non-human primates [109] and iguanas [110,111,112,113]. Animals believed to be less exotic may also contribute to melioidosis transmission; these include canines [114], ornamental fish [107,115] and goats [116]. Zoonotic transmission adds a layer of complexity to the Public Health response needed to control the emergence of melioidosis worldwide [108]. Recently, the first confirmed case of melioidosis in an animal in New Caledonia was identified. B. pseudomallei was isolated from a goat, suggesting possible human–animal transmission. The response involved analysis of the isolated strain using phylogenetics, which confirmed that the strain was related to those found in humans in the area. Recommendations were put in place to avoid further dissemination of the disease, including isolation of infected animals, use of PPE, clinical examination of the rest of the flock and culling of sick animals [116]. The potential zoonotic spread of melioidosis highlights the need for a One Health approach, including surveillance, increasing awareness of animal disease, improving diagnosis and access to diagnostic tools [116,117].

9. Conclusions and Future Perspective

Less than a decade ago, melioidosis was recognized as being endemic in 45 countries worldwide, but modeling studies suggested the disease may be endemic in at least another 30 countries, although a lack of systematic data in regions of South Asia, Africa and the Americas may be underestimating the true number of cases [2,3,108]. The burden of B. pseudomallei globally may, therefore, be greater than predicted. Rising temperatures, rainfall-related events and flooding have been linked with melioidosis, and environmental changes will likely contribute further to the geographical expansion of the disease [3,118].
An additional factor for consideration is the rise in type 2 diabetes observed in tropical countries, which may be undiagnosed or poorly controlled [119]. The majority of patients with diabetes live in low- and middle-income countries, and there is evidence that diabetes increases the severity of some endemic infections, such as melioidosis [119]. Thus, health services in tropical countries may suffer the double burden of infectious and non-communicable diseases [119].
The future perspective for the evolving epidemiology of melioidosis arises in the context of globalization, influenced by population movements, climate change altering the ecological niches of B. pseudomallei, unusual epidemiological epidemic and pandemic situations, and technological advances in medicine paradoxically leading to a greater number of susceptible immunosuppressed or vulnerable patients. Figure 1 summarizes factors that may contribute to the recent changes in the global epidemiology of human melioidosis. All these intertwining factors can create challenges for the management of melioidosis but may also give rise to new opportunities for prevention and control.

Author Contributions

F.F.N. conceptualization, literature review, drafting, proofing, editing and finalizing manuscript; all authors contributed to the literature review, drafting, editing and reviewing the final version of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This research was supported by CIBER—Consorcio Centro de Investigación Biomédica en Red—(CB 2021), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea—NextGenerationEU.

Conflicts of Interest

There are no conflicts of interest to declare.

References

  1. Petras, J.K.; Elrod, M.G.; Ty, M.C.; Dawson, P.; O’Laughlin, K.; Gee, J.E.; Hanson, J.; Boutwell, C.; Ainsworth, G.; Beesley, C.A.; et al. Locally Acquired Melioidosis Linked to Environment—Mississippi, 2020–2023. N. Engl. J. Med. 2023, 389, 2355–2362. [Google Scholar] [CrossRef] [PubMed]
  2. Limmathurotsakul, D.; Golding, N.; Dance, D.A.B.; Messina, J.P.; Pigott, D.M.; Moyes, C.L.; Rolim, D.B.; Bertherat, E.; Day, N.P.J.; Peacock, S.J.; et al. Predicted global distribution of Burkholderia pseudomallei and burden of melioidosis. Nat. Microbiol. 2016, 1, 15008. [Google Scholar] [CrossRef] [PubMed]
  3. Currie, B.J.; Meumann, E.M.; Kaestli, M. The Expanding Global Footprint of Burkholderia pseudomallei and Melioidosis. Am. J. Trop. Med. Hyg. 2023, 108, 1081–1083. [Google Scholar] [CrossRef] [PubMed]
  4. Bauer, I.L. Cyclones and flooding in tropical Northern Australia increase the risk of exposure to melioidosis. J. Travel Med. 2024, 31, taae031. [Google Scholar] [CrossRef] [PubMed]
  5. Gassiep, I.; Grey, V.; Thean, L.J.; Farquhar, D.; Clark, J.E.; Ariotti, L.; Graham, R.; Jennison, A.V.; Bergh, H.; Anuradha, S.; et al. Expanding the Geographic Boundaries of Melioidosis in Queensland, Australia. Am. J. Trop. Med. Hyg. 2023, 108, 1215–1219. [Google Scholar] [CrossRef]
  6. Smith, S.; Marquardt, T.; Jennison, A.V.; D’Addona, A.; Stewart, J.; Yarwood, T.; Ho, J.; Binotto, E.; Harris, J.; Fahmy, M.; et al. Clinical Manifestations and Genomic Evaluation of Melioidosis Outbreak among Children after Sporting Event, Australia. Emerg. Infect. Dis. 2023, 29, 2218–2228. [Google Scholar] [CrossRef]
  7. Tantirat, P.; Chantarawichian, Y.; Taweewigyakarn, P.; Kripattanapong, S.; Jitpeera, C.; Doungngern, P.; Phiancharoen, C.; Tangwangvivat, R.; Hinjoy, S.; Sujariyakul, A.; et al. Melioidosis in Patients with COVID-19 Exposed to Contaminated Tap Water, Thailand, 2021. Emerg. Infect. Dis. 2024, 30, 791–794. [Google Scholar] [CrossRef]
  8. Norman, F.F.; Chen, L.H. Travel-associated melioidosis: A narrative review. J. Travel Med. 2023, 30, taad039. [Google Scholar] [CrossRef]
  9. Dan, M. Melioidosis in Travelers: Review of the Literature. J. Travel Med. 2015, 22, 410–414. [Google Scholar] [CrossRef]
  10. Igea, P.; Quereda, C.; Gomez G De La Pedrosa, E.; Montaño, L.; Tato, M.; Norman, F.F. Melioidosis in a traveller from Africa. J. Travel Med. 2023, 30, taad005. [Google Scholar] [CrossRef]
  11. Demas, A.; Labbé, F.; Vandendriessche, A.; Langlois, V. Focal pachymeningitis in a returning traveler: Don’t forget melioidosis. IDCases 2023, 33, 10–12. [Google Scholar] [CrossRef] [PubMed]
  12. Muhsen, I.N.; Galeano, S.; Niederwieser, D.; Koh, M.B.C.; Ljungman, P.; Machado, C.M.; Kharfan-Dabaja, M.A.; de la Camara, R.; Kodera, Y.; Szer, J.; et al. Endemic or regionally limited bacterial and viral infections in haematopoietic stem-cell transplantation recipients: A Worldwide Network for Blood and Marrow Transplantation (WBMT) Review. Lancet Haematol. 2023, 10, e284–e294. [Google Scholar] [CrossRef] [PubMed]
  13. Speiser, L.J.; Graf, E.H.; Seville, M.T.; Singbartl, K.; Dalton, M.L.; Harrington, D.; Kretschmer, M.; Kuljanin, M.; Zabel, K.; Sunenshine, R.; et al. Burkholderia pseudomallei Laboratory Exposure, Arizona, USA. Emerg. Infect. Dis. 2023, 29, 1061–1063. [Google Scholar] [CrossRef] [PubMed]
  14. Currie, B.J.; Dance, D.A.B.; Cheng, A.C. The global distribution of Burkholderia pseudomallei and melioidosis: An update. Trans. R. Soc. Trop. Med. Hyg. 2008, 102, S1–S4. [Google Scholar] [CrossRef]
  15. Sanchez-Villamil, J.I.; Torres, A.G. Melioidosis in Mexico, Central America, and the Caribbean. Trop. Med. Infect. Dis. 2018, 3, 24. [Google Scholar] [CrossRef]
  16. Steinmetz, I.; Wagner, G.E.; Kanyala, E.; Sawadogo, M.; Soumeya, H.; Teferi, M.; Andargie, E.; Yeshitela, B.; Atsé-Achi, L.Y.; Sanogo, M.; et al. Melioidosis in Africa: Time to uncover the true disease load. Trop. Med. Infect. Dis. 2018, 3, 62. [Google Scholar] [CrossRef]
  17. Mukhopadhyay, C.; Shaw, T.; Varghese, G.M.; Dance, D.A.B. Melioidosis in South Asia (India, Nepal, Pakistan, Bhutan and Afghanistan). Trop. Med. Infect. Dis. 2018, 3, 51. [Google Scholar] [CrossRef]
  18. Rolim, D.B.; Lima, R.X.R.; Ribeiro, A.K.C.; Colares, R.M.; Lima, L.D.Q.; Rodríguez-Morales, A.J.; Montúfar, F.E.; Dance, D.A.B. Melioidosis in South America. Trop. Med. Infect. Dis. 2018, 3, 60. [Google Scholar] [CrossRef]
  19. Sarovich, D.S.; Garin, B.; De Smet, B.; Kaestli, M.; Mayo, M.; Vandamme, P.; Jacobs, J.; Lompo, P.; Tahita, M.C.; Tinto, H.; et al. Phylogenomic Analysis Reveals an Asian Origin for African Burkholderia pseudomallei and Further Supports Melioidosis Endemicity in Africa. mSphere 2016, 1, e00089-15. [Google Scholar] [CrossRef]
  20. Centers for Disease Control and Prevention (CDC). Melioidosis. Available online: https://www.cdc.gov/melioidosis/hcp/clinical-overview/index.html (accessed on 6 September 2024).
  21. Hall, C.M.; Romero-Alvarez, D.; Martz, M.; Santana-Propper, E.; Versluis, L.; Jiménez, L.; Alkishe, A.; Busch, J.D.; Maness, T.; Stewart, J.; et al. Low risk of acquiring melioidosis from the environment in the continental United States. PLoS ONE 2022, 17, e0270997. [Google Scholar] [CrossRef]
  22. Torres, A.G. The public health significance of finding autochthonous melioidosis cases in the continental United States. PLoS Negl. Trop. Dis. 2023, 17, 12–14. [Google Scholar] [CrossRef] [PubMed]
  23. Yuan, L.; Huang, S.M.; Yang, J.H.; Qu, Q.; Liu, Y.; Xiao, Y.W.; Qu, J. A case report of travel-associated infection with melioidosis pneumonia and septicemia. Travel Med. Infect. Dis. 2024, 60, 17–19. [Google Scholar] [CrossRef] [PubMed]
  24. Hasani, M.; Shriya, S.R.; Thahira, M.; Haque, S.; Khan, S.L.; Shaloob, A.; Osman, S. Disseminated Melioidosis Presenting As Sepsis, Neurological Melioidosis, Liver and Prostate Abscess in United Arab Emirates. Eur. J. Case Rep. Intern. Med. 2024, 11, 004415. [Google Scholar] [CrossRef] [PubMed]
  25. Martinez, V.; Oh, J.; Gandhi, M.; Brendon, W.; Lemon, J.K.; Feinstein, A.; Lafortune, A. A Rare Case of Melioidosis in the Bronx. Cureus 2024, 16, e57277. [Google Scholar] [CrossRef] [PubMed]
  26. Gottschalk, C.; Stojković, M.; Zange, S.; Wolf, P.; Klein, J.A.F. A case of pulmonary melioidosis in Germany: A rare differential diagnosis in returning travelers from South-East Asia. Infection 2024, 52, 1671–1676. [Google Scholar] [CrossRef]
  27. Guldemond, A.; Yan, A.; Vidanagamage, A.; Chhabda, S.; Nitkunan, A. An unusual cause of headache. Pract. Neurol. 2024. [Google Scholar] [CrossRef]
  28. Waters, M.; Avery, E.G.; German, G.J.; Krajden, S.; Chen, Y. Melioidosis with septic arthritis in a returning traveller. Can. Med. Assoc. J. 2024, 196, E129–E132. [Google Scholar] [CrossRef]
  29. Im, S.; Paz y Mino, A.; Garces, E.; Altamimi, S. Latent melioidosis activation presenting with urinary tract infection and bacteremia. IDCases 2024, 36, e02007. [Google Scholar] [CrossRef]
  30. Balkhair, A.; Adawi, B.A.; Kumar, P.; Mohammed, S.; Baawain, S.; Harrasi, R.A.; Gallenero, G. Melioidosis in a returned traveler: Case report and review of the imported cases in Oman. IDCases 2024, 37, 02019. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
  31. Meumann, E.M.; Currie, B.J. Approach to melioidosis. CMI Commun. 2024, 1, 100008. [Google Scholar] [CrossRef]
  32. Meumann, E.M.; Limmathurotsakul, D.; Dunachie, S.J.; Wiersinga, W.J.; Currie, B.J. Burkholderia pseudomallei and melioidosis. Nat. Rev. Microbiol. 2024, 22, 155–169. [Google Scholar] [CrossRef] [PubMed]
  33. Currie, B.J.; Mayo, M.; Ward, L.M.; Kaestli, M.; Meumann, E.M.; Webb, J.R.; Woerle, C.; Baird, R.W.; Price, R.N.; Marshall, C.S.; et al. The Darwin Prospective Melioidosis Study: A 30-year prospective, observational investigation. Lancet Infect. Dis. 2021, 21, 1737–1746. [Google Scholar] [CrossRef] [PubMed]
  34. Chantratita, N.; Phunpang, R.; Yarasai, A.; Dulsuk, A.; Yimthin, T.; Onofrey, L.A.; Coston, T.D.; Thiansukhon, E.; Chaisuksant, S.; Tanwisaid, K.; et al. Characteristics and one year outcomes of melioidosis patients in Northeastern Thailand: A prospective, multicenter cohort study. Lancet Reg. Health Southeast Asia 2023, 9, 100118. [Google Scholar] [CrossRef] [PubMed]
  35. Baker, K.; Smith, S.; Stewart, J.; Withey, G.; Bain, M.; Pridgeon, S.; Hanson, J. Melioidosis of the Female Genitourinary Tract. Am. J. Trop. Med. Hyg. 2023, 109, 1233–1237. [Google Scholar] [CrossRef]
  36. Cheng, A.C.; Wuthiekanun, V.; Limmathurotsakul, D.; Chierakul, W.; Peacock, S.J. Intensity of exposure and incidence of melioidosis in Thai children. Trans. R. Soc. Trop. Med. Hyg. 2008, 102, S37–S39. [Google Scholar] [CrossRef]
  37. Schwartzman, G.; Reddy, S.A.; Berg, S.H.; Currie, B.J.; Saavedra, A.P. Cutaneous melioidosis: An updated review and primer for the dermatologist. J. Am. Acad. Dermatol. 2023, 89, 1201–1208. [Google Scholar] [CrossRef]
  38. Diolombi, M.; Seneviratne, M.; Norton, R. Case Report: Erythema Nodosum and Melioidosis: An Unreported Association. Am. J. Trop. Med. Hyg. 2020, 103, 1841–1843. [Google Scholar] [CrossRef]
  39. Tantawarak, N.; Techasatian, L.; Ungarreevittaya, P.; Kosalaraksa, P.; Lumbiganon, P. Case Report: Melioidosis-Related Severe Cutaneous Features of Erythema Nodosum in a Thai Child. Am. J. Trop. Med. Hyg. 2024, 110, 133–135. [Google Scholar] [CrossRef]
  40. Chandna, A.; Bonhoeffer, M.; Miliya, T.; Suy, K.; Sao, S.; Turner, P. Improving Treatment and Outcomes for Melioidosis in Children, Northern Cambodia, 2009–2018. Emerg. Infect. Dis. 2021, 27, 1169–1172. [Google Scholar] [CrossRef]
  41. Pham, T.S.; König, E.; Bui, T.T.; Vu, T.N.A.; Nguyen, T.N.; Do, C.V.; Lichtenegger, S.; Bui, N.H.L.; Trinh, H.T.; Steinmetz, I.; et al. Newly detected paediatric melioidosis cases in a single referral children’s hospital in Ho Chi Minh City indicate the probable underrecognition of melioidosis in South Vietnam. Trans. R. Soc. Trop. Med. Hyg. 2023, 118, 190–198. [Google Scholar] [CrossRef]
  42. Mohan, A.; Podin, Y.; Liew, D.-W.; Mahendra Kumar, J.; Lau, P.S.-T.; Tan, Y.-Y.; Tai, Y.-P.; Gill, R.S.; Shanmugam, R.; Chien, S.-L.; et al. Fine-needle aspiration to improve diagnosis of melioidosis of the head and neck in children: A study from Sarawak, Malaysia. BMC Infect. Dis. 2021, 21, 1069. [Google Scholar] [CrossRef] [PubMed]
  43. Thatrimontrichai, A.; Maneenil, G. Neonatal Melioidosis. Pediatr. Infect. Dis. J. 2012, 31, 1195–1197. [Google Scholar] [CrossRef] [PubMed]
  44. Kozlowska, J.; Smith, S.; Roberts, J.; Pridgeon, S.; Hanson, J. Prostatic Abscess due to Burkholderia pseudomallei: Facilitating Diagnosis to Optimize Management. Am. J. Trop. Med. Hyg. 2018, 98, 227–230. [Google Scholar] [CrossRef] [PubMed]
  45. Saïdani, N.; Griffiths, K.; Million, M.; Gautret, P.; Dubourg, G.; Parola, P.; Brouqui, P.; Lagier, J.-C. Melioidosis as a travel-associated infection: Case report and review of the literature. Travel Med. Infect. Dis. 2015, 13, 367–381. [Google Scholar] [CrossRef] [PubMed]
  46. Morse, L.P.; Moller, C.-C.B.; Harvey, E.; Ward, L.; Cheng, A.C.; Carson, P.J.; Currie, B.J. Prostatic Abscess Due to Burkholderia pseudomallei: 81 Cases From a 19-Year Prospective Melioidosis Study. J. Urol. 2009, 182, 542–547. [Google Scholar] [CrossRef]
  47. Porter, M.C.; Pennell, C.E.; Woods, P.; Dyer, J.; Merritt, A.J.; Currie, B.J. Case Report: Chorioamnionitis and Premature Delivery due to Burkholderia pseudomallei Infection in Pregnancy. Am. J. Trop. Med. Hyg. 2018, 98, 797–799. [Google Scholar] [CrossRef]
  48. Le Tohic, S.; Montana, M.; Koch, L.; Curti, C.; Vanelle, P. A review of melioidosis cases imported into Europe. Eur. J. Clin. Microbiol. Infect. Dis. 2019, 38, 1395–1408. [Google Scholar] [CrossRef]
  49. Fertitta, L.; Monsel, G.; Torresi, J.; Caumes, E. Cutaneous melioidosis: A review of the literature. Int. J. Dermatol. 2019, 58, 221–227. [Google Scholar] [CrossRef]
  50. Smith, S.; Munas, A.M.; Hanson, J. Hemophagocytic Lymphohistiocytosis Complicating Melioidosis. Am. J. Trop. Med. Hyg. 2018, 99, 557–558. [Google Scholar] [CrossRef]
  51. Devi, S.; Dash, A.; Dey, A.; Patra, S.; Sahoo, B.; Mahapatra, A.; Dalei, S. Hemophagocytic lymphohistiocytosis complicating septicemic melioidosis: A case report. J. Infect. Chemother. 2024; in press. [Google Scholar] [CrossRef]
  52. Sui, M.-Z.; Wan, K.-C.; Chen, Y.-L.; Li, H.-L.; Wang, S.-S.; Chen, Z.-F. Fatal hemophagocytic lymphohistiocytosis-induced multiorgan dysfunction secondary to Burkholderia pseudomallei sepsis: A case report. World J. Clin. Cases 2023, 11, 7372–7379. [Google Scholar] [CrossRef] [PubMed]
  53. al Waseem, S.M.H.; Antony, T.; Suresh, S.; Gopalan, S. Haemophagocytic lymphohistiocytosis due to Burkholderia pseudomallei in a primigravida. Access Microbiol. 2023, 5, 000520. [Google Scholar] [CrossRef] [PubMed]
  54. Beig, J.; Read, K.; Welch, D.; Bhally, H. Melioidosis with possible Haemophagocytic lymphohistiocytosis. N. Z. Med. J. 2017, 130, 76–79. [Google Scholar] [PubMed]
  55. Gassiep, I.; Armstrong, M.; Norton, R. Human Melioidosis. Clin. Microbiol. Rev. 2020, 33, 10-1128. [Google Scholar] [CrossRef] [PubMed]
  56. John, G.T.; Ahmed, I.; Jacob, C.K.; Jesudason, M.V.; Lalitha, M.K. Melioidosis in a renal transplant recipient. Transplantation 2003, 76, 262. [Google Scholar] [CrossRef]
  57. Varughese, S.; Mohapatra, A.; Sahni, R.; Balaji, V.; Tamilarasi, V. Renal allograft recipient with melioidosis of the urinary tract. Transpl. Infect. Dis. 2011, 13, 95–96. [Google Scholar] [CrossRef]
  58. Sathiavageesan, S. Septicemic melioidosis in a transplant recipient causing graft dysfunction. Indian J. Nephrol. 2016, 26, 379. [Google Scholar] [CrossRef]
  59. Koshy, M.; Jagannati, M.; Ralph, R.; Victor, P.; David, T.; Sathyendra, S.; Veeraraghavan, B.; Varghese, G.M. Clinical Manifestations, Antimicrobial Drug Susceptibility Patterns, and Outcomes in Melioidosis Cases, India. Emerg. Infect. Dis. 2019, 25, 316–320. [Google Scholar] [CrossRef]
  60. Muthina, R.A.; Koppara, N.K.; Bethasaida Manuel, M.; Bommu, A.N.; Anapalli, S.R.; Boju, S.L.; Rapur, R.; Vishnubotla, S.K. Cerebral abscess and calvarial osteomyelitis caused by Burkholderia pseudomallei in a renal transplant recipient. Transpl. Infect. Dis. 2021, 23, e13530. [Google Scholar] [CrossRef]
  61. Wiersinga, W.J.; Virk, H.S.; Torres, A.G.; Currie, B.J.; Peacock, S.J.; Dance, D.A.B.; Limmathurotsakul, D. Melioidosis. Nat. Rev. Dis. Prim. 2018, 4, 17107. [Google Scholar] [CrossRef]
  62. Bansal, S.B.; Ramasubramanian, V.; Prasad, N.; Saraf, N.; Soman, R.; Makharia, G.; Varughese, S.; Sahay, M.; Deswal, V.; Jeloka, T.; et al. South Asian Transplant Infectious Disease Guidelines for Solid Organ Transplant Candidates, Recipients, and Donors. Transplantation 2023, 107, 1910–1934. [Google Scholar] [CrossRef]
  63. Jabbar, Z.; Currie, B.J. Melioidosis and the kidney. Nephrology 2013, 18, 169–175. [Google Scholar] [CrossRef]
  64. Chierakul, W.; Wuthiekanun, V.; Chaowagul, W.; Amornchai, P.; Cheng, A.C.; White, N.J.; Day, N.P.J.; Peacock, S.J. Short report: Disease severity and outcome of melioidosis in HIV coinfected individuals. Am. J. Trop. Med. Hyg. 2005, 73, 1165–1166. [Google Scholar] [CrossRef]
  65. Fertitta, L.; Monsel, G.; Delaroche, M.; Fourniols, E.; Brossier, F.; Caumes, E. Cutaneous melioidosis: Two cases of chronic primary forms. J. Eur. Acad. Dermatol. Venereol. 2018, 32, 1165–1166. [Google Scholar] [CrossRef]
  66. Martin de Frémont, G.; Gominet, M.; Bousquet, A.; Gervaise, A.; Andriamanantena, D.; Ficko, C. Burkholderia pseudomallei . AIDS 2019, 33, 1403–1404. [Google Scholar] [CrossRef]
  67. Gulati, U.; Nanduri, A.C.; Juneja, P.; Kaufman, D.; Elrod, M.G.; Kolton, C.B.; Gee, J.E.; Garafalo, K.; Blaney, D.D. Case Report: A Fatal Case of Latent Melioidosis Activated by COVID-19. Am. J. Trop. Med. Hyg. 2022, 106, 1170–1172. [Google Scholar] [CrossRef]
  68. Baker, K.; Duncan, T.; Kung, S.; Smith, S.; Hanson, J. Melioidosis masquerading as malignancy in tropical Australia; Lessons for clinicians and implications for clinical management. Acta Trop. 2024, 254, 107209. [Google Scholar] [CrossRef]
  69. Kho, S.S.; Ho, Y.F.; Chan, S.K.; Tie, S.T. Mediastinal melioidosis masquerading as malignancy of the lung. Lancet 2021, 397, e8. [Google Scholar] [CrossRef]
  70. Liang, C.-C.; Chen, S.-Y.; Chen, T.-Y.; Chen, S.-T. Central Nervous System Melioidosis Mimics Malignancy: A Case Report and Literature Review. World Neurosurg. 2016, 89, 732.e19–732.e23. [Google Scholar] [CrossRef]
  71. Lin, H.P.; Puthucheary, S.D.; Sinniah, D. Acute Septicemic Melioidosis Occurring in a Child with Acute Lymphoblastic Leukemia. Clin. Pediatr. 1980, 19, 697–699. [Google Scholar] [CrossRef]
  72. Mukhopadhyay, C.; Chawla, K.; Vandana, K.E.; Krishna, S.; Saravu, K. Pulmonary melioidosis in febrile neutropenia: The rare and deadly duet. Trop. Doct. 2010, 40, 165–166. [Google Scholar] [CrossRef] [PubMed]
  73. Sukauichai, S.; Pattarowas, C. Melioidosis with Septic Shock and Disseminated Infection in a Neutropenic Patient Receiving Chemotherapy. Case Rep. Infect. Dis. 2020, 2020, 8976180. [Google Scholar] [CrossRef] [PubMed]
  74. Laplertsakul, G.; Sutherasan, Y.; Suwatanapongched, T.; Incharoen, P.; Petnak, T. Non-Small Cell Lung Carcinoma with Concomitant Localized Pulmonary Melioidosis: A Rare Co-Existing Disease. Infect. Drug Resist. 2020, 13, 2957–2961. [Google Scholar] [CrossRef] [PubMed]
  75. Rossi, B.; Epelboin, L.; Jauréguiberry, S.; Lecso, M.; Roos-Weil, D.; Gabarre, J.; Grenier, P.A.; Bricaire, F.; Caumes, E. Melioidosis and Hairy Cell Leukemia in 2 Travelers Returning from Thailand. Emerg. Infect. Dis. 2013, 19, 503–505. [Google Scholar] [CrossRef] [PubMed]
  76. Birnie, E.; Savelkoel, J.; Reubsaet, F.; Roelofs, J.J.T.H.; Soetekouw, R.; Kolkman, S.; Cremers, A.L.; Grobusch, M.P.; Notermans, D.W.; Wiersinga, W.J.; et al. Melioidosis in travelers: An analysis of Dutch melioidosis registry data 1985–2018. Travel Med. Infect. Dis. 2019, 32, 101461. [Google Scholar] [CrossRef]
  77. Beeker, A.; Van de Stadt, K.; Bakker, K. Melioidosis. Neth. J. Med. 1999, 54, 76–79. [Google Scholar] [CrossRef]
  78. Donahue, M.A.; Newcomb, G.; Spinella, S.; Prasad, P.; Liesveld, J.; Egan, C.T.; Smith, G.L.; Newman, A.P.; Bower, W.A.; Blaney, D.D.; et al. CNS Melioidosis in a Traveler Returning from Cabo, Mexico. Open Forum Infect. Dis. 2019, 6, ofz005. [Google Scholar] [CrossRef]
  79. Pasupneti, T.; Munekata, M.; Saith, S.; Filler, S. Disseminated melioidosis in a patient from Nicaragua. IDCases 2021, 26, e01318. [Google Scholar] [CrossRef]
  80. Commons, R.J.; Grivas, R.; Currie, B.J. Melioidosis in a patient on monoclonal antibody therapy for psoriatic arthritis. Intern. Med. J. 2014, 44, 1245–1246. [Google Scholar] [CrossRef]
  81. Che Rahim, M.J.; Mohammad, N.; Kamaruddin, M.I.; Wan Ghazali, W.S. Systemic lupus erythematosus and melioidosis. BMJ Case Rep. 2019, 12, e229974. [Google Scholar] [CrossRef]
  82. Wiwanitkit, V. Coinfection dengue and melioidosis infection. Rev. Soc. Bras. Med. Trop. 2012, 45, 657–658. [Google Scholar] [CrossRef] [PubMed]
  83. Macedo, R.N.; Rocha, F.A.; Rolim, D.B.; Vilar, D.C.L.F.; Araújo, F.M.d.C.; Vieira, N.N.; Teixeira, J.R.; Carvalho, M.C.; Oliveira, F.G.M.; Cavalcanti, L.P.d.G. Severe coinfection of melioidosis and dengue fever in northeastern Brazil: First case report. Rev. Soc. Bras. Med. Trop. 2012, 45, 132–133. [Google Scholar] [CrossRef] [PubMed]
  84. Li, X.Y.; Ke, B.X.; Chen, C.N.; Xiao, H.L.; Liu, M.Z.; Xiong, Y.C.; Bai, R.; Chen, J.D.; Ke, C.W. First co-infection case of melioidosis and Japanese encephalitis in China. BMC Infect. Dis. 2018, 18, 452. [Google Scholar] [CrossRef] [PubMed]
  85. Tan, W.F.; Lee, H.G. Concurrent Influenza A and Pulmonary Melioidosis in pregnancy. Med. J. Malays. 2021, 76, 245–247. [Google Scholar]
  86. Mackowiak, P.A. Septicemic melioidosis. Occurrence following acute influenza A six years after exposure in Vietnam. JAMA J. Am. Med. Assoc. 1978, 240, 764–766. [Google Scholar] [CrossRef]
  87. Vithiya, G.; Rajendran, T.; Velvizhi, S.; Ramesh, A. Pulmonary tuberculosis and neurologic melioidosis coinfection-first case report from Madurai. Indian J. Med. Microbiol. 2023, 46, 100458. [Google Scholar] [CrossRef]
  88. Rubel, A.R.; Mani, B.I.; Kishore, P.V.; Chong, V.H. Pulmonary tuberculosis and melioidosis coinfection in Brunei Darussalam: The importance of awareness and screening. West. Pac. Surveill. Response J. 2022, 13, 43–48. [Google Scholar] [CrossRef]
  89. Sriwijitalai, W.; Wiwanitkit, V. Concurrent melioidosis and tuberculosis: An expected incidence in endemic tropical country. Int. J. Mycobacteriol. 2019, 8, 412. [Google Scholar] [CrossRef]
  90. Tan, S.Y. Tuberculosis and Melioidosis at Distinct Sites Occurring Simultaneously. Case Rep. Infect. Dis. 2020, 2020, 9818129. [Google Scholar] [CrossRef]
  91. Jain, M.; Ratna, H.V.K.; Mohanty, S.; Padhi, S.; Tripathy, S. Coinfection of Melioidosis and Tuberculosis Causing Infective Lumbar Spondylodiscitis. JBJS Case Connect. 2023, 13, e22. [Google Scholar] [CrossRef]
  92. Hin, H.S.; Ramalingam, R.; Chunn, K.Y.; Ahmad, N.; Ab Rahman, J.; Mohamed, M.S. Fatal Co-Infection–Melioidosis and Leptospirosis. Am. Soc. Trop. Med. Hyg. 2012, 87, 737–740. [Google Scholar] [CrossRef] [PubMed]
  93. Sapian, M.; Khair, M.T.; How, S.H.; Rajalingam, R.; Sahhir, K.; Norazah, A.; Khebir, V.; Jamalludin, A.R. Outbreak of melioidosis and leptospirosis co-infection following a rescue operation. Med. J. Malays. 2012, 67, 293–297. [Google Scholar]
  94. Gunasena, J.; De Silva, S. Double-trouble: A rare case of co-infection with melioidosis and leptospirosis from Sri Lanka. Trop. Doct. 2023, 53, 332–337. [Google Scholar] [CrossRef] [PubMed]
  95. Lu, P.; Tseng, S. Fatal Septicemic Melioidosis in a Young Military Person Possibly Co-Infected with Leptospira interrogans and Orientia tsutsugamushi. Kaohsiung J. Med. Sci. 2005, 21, 173–178. [Google Scholar] [CrossRef]
  96. Mohd Ali, M.R.; Mohamad Safiee, A.W.; Thangarajah, P.; Fauzi, M.H.; Muhd Besari, A.; Ismail, N.; Yean Yean, C. Molecular detection of leptospirosis and melioidosis co-infection: A case report. J. Infect. Public Health 2017, 10, 894–896. [Google Scholar] [CrossRef]
  97. Azri, M.; Ismail, I.H. First documented co-infection case of cat-scratch disease and melioidosis in Malaysia: A cause of undifferentiated prolonged febrile illness. Med. J. Malays. 2022, 77, 255–257. [Google Scholar]
  98. Kahandawaarachchi, I.C.I.; Premawansa, G.S.; Warnasuriya, W.; Dassanayake, M.; Corea, E. A case report of co-infection of Melioidosis and cutaneous Leishmaniasis. BMC Infect. Dis. 2017, 17, 533. [Google Scholar] [CrossRef]
  99. Schlech, W.F.; Turchik, J.B.; Westlake, R.E.; Klein, G.C.; Band, J.D.; Weaver, R.E. Laboratory-Acquired Infection with Pseudomonas pseudomallei (Melioidosis). N. Engl. J. Med. 1981, 305, 1133–1135. [Google Scholar] [CrossRef]
  100. Peacock, S.J.; Schweizer, H.P.; Dance, D.A.B.; Smith, T.L.; Gee, J.E.; Wuthiekanun, V.; DeShazer, D.; Steinmetz, I.; Tan, P.; Currie, B.J. Management of Accidental Laboratory Exposure to Burkholderia pseudomallei and B. mallei. Emerg. Infect. Dis. 2008, 14, e2. [Google Scholar] [CrossRef]
  101. Bousquet, A.; Gueudet, T.; Biot, F.; Bigaillon, C.; Gominet, M.; Mérens, A. Accidental exposure to Burkholderia pseudomallei: Awareness is also needed for urine specimens. Clin. Microbiol. Infect. 2020, 26, 265–266. [Google Scholar] [CrossRef]
  102. Ashdown, L.R. Nosocomial Infection Due to Pseudomonas pseudomallei: Two Cases and an Epidemiologic Study. Clin. Infect. Dis. 1979, 1, 891–894. [Google Scholar] [CrossRef] [PubMed]
  103. Markovitz, A. Inoculation by bronchoscopy. West. J. Med. 1979, 131, 550. [Google Scholar] [PubMed]
  104. Merritt, A.J.; Peck, M.; Gayle, D.; Levy, A.; Ler, Y.-H.; Raby, E.; Gibbs, T.M.; Inglis, T.J.J. Cutaneous Melioidosis Cluster Caused by Contaminated Wound Irrigation Fluid. Emerg. Infect. Dis. 2016, 22, 1420–1427. [Google Scholar] [CrossRef] [PubMed]
  105. Gal, D.; Mayo, M.; Smith-Vaughan, H.; Dasari, P.; McKinnon, M.; Jacups, S.P.; Urquhart, A.I.; Hassell, M.; Currie, B.J. Contamination of hand wash detergent linked to occupationally acquired melioidosis. Am. J. Trop. Med. Hyg. 2004, 71, 360–362. [Google Scholar] [CrossRef]
  106. Gee, J.E.; Bower, W.A.; Kunkel, A.; Petras, J.; Gettings, J.; Bye, M.; Firestone, M.; Elrod, M.G.; Liu, L.; Blaney, D.D.; et al. Multistate Outbreak of Melioidosis Associated with Imported Aromatherapy Spray. N. Engl. J. Med. 2022, 386, 861–868. [Google Scholar] [CrossRef]
  107. Dawson, P.; Duwell, M.M.; Elrod, M.G.; Thompson, R.J.; Crum, D.A.; Jacobs, R.M.; Gee, J.E.; Kolton, C.B.; Liu, L.; Blaney, D.D.; et al. Human melioidosis caused by novel transmission of Burkholderia pseudomallei from Freshwater Home Aquarium, United States. Emerg. Infect. Dis. 2021, 27, 3030–3035. [Google Scholar] [CrossRef]
  108. Birnie, E.; Biemond, J.J.; Wiersinga, W.J. Drivers of melioidosis endemicity: Epidemiological transition, zoonosis, and climate change. Curr. Opin. Infect. Dis. 2022, 35, 196–204. [Google Scholar] [CrossRef]
  109. Taetzsch, S.J.; Swaney, E.M.; Gee, J.E.; Hidalgo, P.M.; Broussard, K.R.; Martines, R.B.; Blaney, D.D.; Galland, G.G.; Gulvik, C.A.; Marston, C.K.; et al. Melioidosis in Cynomolgus Macaques (Macaca fascicularis) Imported to the United States from Cambodia. Comp. Med. 2022, 72, 394–402. [Google Scholar] [CrossRef]
  110. Hellebuyck, T.; Wattiau, P.; Boyen, F.; Moeremans, I.; Roosens, N.H.; Vanneste, K.; Garmyn, A.; Saey, V.; Pasmans, F.; Haesebrouck, F. Isolation of Burkholderia pseudomallei from a pet green iguana, Belgium. Emerg. Infect. Dis. 2018, 24, 2331–2333. [Google Scholar] [CrossRef]
  111. Zehnder, A.M.; Hawkins, M.G.; Koski, M.A.; Lifland, B.; Byrne, B.A.; Swanson, A.A.; Rood, M.P.; Gee, J.E.; Elrod, M.G.; Beesley, C.A.; et al. Burkholderia pseudomallei isolates in 2 pet iguanas, California, USA. Emerg. Infect. Dis. 2014, 20, 304–306. [Google Scholar] [CrossRef]
  112. Rodari, P.; Tamarozzi, F.; Tais, S.; Degani, M.; Perandin, F.; Buonfrate, D.; Nicastri, E.; Lepore, L.; Giancola, M.L.; Carrara, S.; et al. Prevalence of Chagas disease and strongyloidiasis among HIV-infected Latin American immigrants in Italy—The CHILI study. Travel Med. Infect. Dis. 2022, 48, 102324. [Google Scholar] [CrossRef] [PubMed]
  113. Elschner, M.C.; Hnizdo, J.; Stamm, I.; El-Adawy, H.; Mertens, K.; Melzer, F. Isolation of the highly pathogenic and zoonotic agent Burkholderia pseudomallei from a pet green Iguana in Prague, Czech Republic. BMC Vet. Res. 2014, 10, 283. [Google Scholar] [CrossRef] [PubMed]
  114. Ryan, C.W.; Bishop, K.; Blaney, D.D.; Britton, S.J.; Cantone, F.; Egan, C.; Elrod, M.G.; Frye, C.W.; Maxted, A.M.; Perkins, G. Public health response to an imported case of canine melioidosis. Zoonoses Public Health 2018, 65, 420–424. [Google Scholar] [CrossRef] [PubMed]
  115. Venkatesan, T.; Siritana, V.; Silisouk, J.; Roberts, T.; Robinson, M.T.; Dance, D.A.B. Burkholderia pseudomallei Bacteria in Ornamental Fish Tanks, Vientiane, Laos, 2023. Emerg. Infect. Dis. 2024, 30, 599–600. [Google Scholar] [CrossRef] [PubMed]
  116. Desoutter, A.; Deshayes, T.; Vorimore, F.; Klotoe, B.; Durand, B.; Colot, J.; Wagner-Lichtenegger, G.; Steinmetz, I.; Tuanyok, A.; Laroucau, K. Isolation of Burkholderia pseudomallei from a goat in New Caledonia: Implications for animal and human health monitoring and serological tool comparison. BMC Vet. Res. 2024, 20, 114. [Google Scholar] [CrossRef] [PubMed]
  117. Rees, E.M.; Minter, A.; Edmunds, W.J.; Lau, C.L.; Kucharski, A.J.; Lowe, R. Transmission modelling of environmentally persistent zoonotic diseases: A systematic review. Lancet Planet. Health 2021, 5, e466–e478. [Google Scholar] [CrossRef]
  118. Kaestli, M.; Grist, E.P.M.; Ward, L.; Hill, A.; Mayo, M.; Currie, B.J. The association of melioidosis with climatic factors in Darwin, Australia: A 23-year time-series analysis. J. Infect. 2016, 72, 687–697. [Google Scholar] [CrossRef]
  119. van Crevel, R.; van de Vijver, S.; Moore, D.A.J. The global diabetes epidemic: What does it mean for infectious diseases in tropical countries? Lancet Diabetes Endocrinol. 2017, 5, 457–468. [Google Scholar] [CrossRef]
Pathogens 13 00926 g001
Figure 1. Factors that may contribute to recent changes in the global epidemiology of human melioidosis [4,5,7,8,9,30,99,106,108,119].
Figure 1. Factors that may contribute to recent changes in the global epidemiology of human melioidosis [4,5,7,8,9,30,99,106,108,119].
Pathogens 13 00926 g001
Table 1. Main characteristics of travel-associated melioidosis.
Table 1. Main characteristics of travel-associated melioidosis.
Previous Literature Reviews—Summary and Main Features
Year
Reference
Number Cases (n)		Gender/AgeCountry Exposure → DiagnosisMain Risk FactorsClinical PresentationDiagnosisTreatmentTime Return-Onset Symptom Duration-DiagnosisDuration TravelOutcome
Comments
Dan M, 2015 [9]
n = 75
(1982–2015)		76.4% male
Mean age 49.6 (4–90) years		Thailand (46%)
Vietnam (8%) → Western Europe (69.5%)		Diabetes (21%)
Chronic lung disease/ smoking (11%)
Liver disease- alcoholism (7%)		Sepsis (34%)
Pneumonia (29%)
Abscess formation (25%)		NANAMean 3 weeks (range 0–52 weeks)NAMean 36 days (range 7–330 days)Mortality 17%
Norman et al., 2023 [8]
n = 137
(2016–2022)		71% male
Age range 15–83 years		Thailand (41%)
India (9%)→
UK (40%)
Netherlands (20%)		Diabetes (25%)
Chronic lung disease (9%)
Liver disease (5%)		Pneumonia (35%)
Sepsis (30%)
SSTI (14%)		NAIV phase
Ceftazidime (52%)
Meropenem (41%)
Continuation phase
Co-trimoxazole (82%)		Less than 1 week (55%)
More than 12 weeks (29%)		<1 week–18 monthsRange from 9 days (travelers) to 10 years (expatriates)Mortality 13%
Newly reported cases 2023–mid-2024
Year
Reference		Gender/AgeCountry exposure → diagnosisRisk factorsClinical presentationDiagnosisTreatmenttime return-onsetSymptom duration-diagnosisDuration travelOutcome
Comments
Demas et al.
2023 [11]		Male
5th decade of life		Thailand→
France		DiabetesPneumonia
Meningitis		BC: initially misidentified as B. thailandensis
PCR confirmed Burkholderia pseudomallei		Amoxicillin
Levofloxacin
Meropenem
−> Co-trimoxazole		NANANASurvived
Igea et al.
2023 [10]		Male
48 years old		Mauritania→
Spain		DiabetesCavitated pneumonia
Necrotic mediastinal lymph nodes
Cutaneous abscesses
Septic arthritis		BC, cutaneous abscess and joint fluid culture: B. pseudomalleiMeropenem + co-trimoxazole
−> co-trimoxazole		4 weeks1 weekNASurvived
Hasani et al.
2024 [24]		Male
40 years old		Philippines→
UAE		Diabetes
Alcohol use
Animal farm		Sepsis
Pneumonia
Liver and prostatic abscess		BC:
B. pseudomallei		Ceftazidime
Meropenem
+
Co-trimoxazole−>co-trimoxazole		NANANASurvived
Martinez et al.
2024 [25]		Male
67 years old		Honduras→
USA		DiabetesSepsis
Altered mental status (encephalopathy)
Liver abscess		BC
B. pseudomallei (initially misidentified as B. thailandensis)		Meropenem −>
Co-trimoxazole		Onset during travelLess than 1 weekNASurvived
Laboratory exposures (prophylaxis offered, no seroconversions)
Gottschalk et al.
2024 [26]		Female
46 years old		Thailand→
Germany		No risk factors identifiedLung cavitation
Mediastinal mass		Mediastinal lymphnodes PCR
B. pseudomallei
Positive serology		Ceftazidime
Co-trimoxazole −> co-amoxiclav		3 weeks4 weeks6 monthsSurvived
Rash with co-trimoxazole
Guldemond et al.
2024 [27]		Female
57 years old		Sri Lanka→
UK		Pre-diabetes
Alpha thalassemia trait		Cerebral abscessCerebral abscess culture: B. pseudomalleiMeropenem + co-trimoxazole
Ceftazidime + doxycycline		Onset during travel10 weeksNASurvived
Neutropenia with co-trimoxazole
Deranged LFTs
Waters et al.
2024 [28]		Female
64 years old		India→
Canada		Diabetes
Walked barefoot in brackish water (Chilika Lake)		Septic arthritisJoint aspiration culture:
initially misidentified as B. thailandensis
PCR confirmed B. pseudomallei		Meropenem + co-trimoxazole
Ceftazidime + co-trimoxazole−>
co-trimoxazole doxycycline		6 weeksLess than 1 weekNASurvived
Thrombocytopenia with co-trimoxazole
Balkhair et al.
2024 [30]		Male
65 years old		Thailand→
Oman		CKD
Water splashes		Pneumonia
Acute on chronic renal failure		BC: initially misidentified as B. thailandensis
PCR confirmed as B. pseudomallei
Sputum culture also positive		Ceftazidime + co-trimoxazoleOnset during travel1 week2 weeksSurvived
Im et al.
2024 [29]		Female
68 years old		Cambodia→
USA		Diabetes
CKD
Contact with animals (goat)		UTIBC and urine culture: B. pseudomalleiCeftazidime
−> co-trimoxazole
Doxycycline		NA24 weeksNASurvived
Pancytopenia with co-trimoxazole
Yuan et al. 2024 [23]Male
56 years old		Myanmar −> ChinaDiabetes
Metal mining		PneumoniaBC WGS
B. pseudomallei
BA, culture, WGS: B. pseudomallei		Meropenem + levofloxacinNA16 weeksNASurvived
SSTI: skin and soft tissue infection; BC: blood cultures; PCR: Polymerase chain reaction; LFTs: liver function tests; CKD: chronic kidney disease; WGS: whole genome sequencing; BAL: bronchoalveolar lavage; NA: not available.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Norman, F.F.; Blair, B.M.; Chamorro-Tojeiro, S.; González-Sanz, M.; Chen, L.H. The Evolving Global Epidemiology of Human Melioidosis: A Narrative Review. Pathogens 2024, 13, 926. https://doi.org/10.3390/pathogens13110926

AMA Style

Norman FF, Blair BM, Chamorro-Tojeiro S, González-Sanz M, Chen LH. The Evolving Global Epidemiology of Human Melioidosis: A Narrative Review. Pathogens. 2024; 13(11):926. https://doi.org/10.3390/pathogens13110926

Chicago/Turabian Style

Norman, Francesca F., Barbra M. Blair, Sandra Chamorro-Tojeiro, Marta González-Sanz, and Lin H. Chen. 2024. "The Evolving Global Epidemiology of Human Melioidosis: A Narrative Review" Pathogens 13, no. 11: 926. https://doi.org/10.3390/pathogens13110926

APA Style

Norman, F. F., Blair, B. M., Chamorro-Tojeiro, S., González-Sanz, M., & Chen, L. H. (2024). The Evolving Global Epidemiology of Human Melioidosis: A Narrative Review. Pathogens, 13(11), 926. https://doi.org/10.3390/pathogens13110926

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop